PsA TNF 부적절한 반응자 환자에서 Guselkumab 대 Golimumab (EVOLUTION)
PsA TNF 부적절한 반응자 환자의 Guselkumab 대 Golimumab: 실용적인 시험(진화)
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The primary aim of the trial will be to determine, among psoriatic arthritis (PsA) patients with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi), whether switching to a new mechanism of action (MOA), specifically guselkumab (GUS), a selective interleukin 23 inhibitor (IL23i) targeting the p19 subunit, is more effective than switching to another TNFi. The primary hypothesis of this study is that switching to a new MOA may be more effective than switching to a second TNFi. This will be the first trial to test such a switch in PsA patients. Additionally, the proposed study will address the effectiveness of a new therapy, GUS, in a clinical practice setting among patients who are TNF IR.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Florida
-
Loxahatchee Groves, Florida, 미국, 33470
- Family Arthritis Center
-
Plant City, Florida, 미국, 33563
- Healing Rheumatology
-
Riverview, Florida, 미국, 33569
- Southwest Florida Rheumatology
-
-
Georgia
-
Lilburn, Georgia, 미국, 30047
- Parris and Associates
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01655
- University of Massachusetts Chan Medical School
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, 미국, 10016
- New York University
-
-
Ohio
-
Blue Ash, Ohio, 미국, 45242
- Cincy Arthritis
-
Wheelersburg, Ohio, 미국, 45694
- Southern Ohio Rheumatology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Hospital at the University of Pennsylvania
-
-
Tennessee
-
Crossville, Tennessee, 미국, 38555
- Cumberland Rheumatology
-
-
Texas
-
Colleyville, Texas, 미국, 76034
- Heritage Rheumatology and Arthritis Care
-
El Paso, Texas, 미국, 79902
- Texas Arthritis Center
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- University of Utah
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Psoriatic arthritis meeting CASPAR criteria;
- Active psoriatic arthritis defined by at least 1 swollen joint;
- cDAPSA score ≥ 10; See also Exclusion #4 - cDAPSA must be > 14 in patients without psoriasis.
- Using a TNFi or previously used a single TNFi historically and either never responded or lost response (TNF IR) and planning to switch to a new biologic therapy;
- If using an oral small molecule/csDMARD (i.e., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, or apremilast), must be on a stable dose for 4 weeks and remain on a stable dose during the study; Use of up to two OSM/csDMARDs is allowed.
- If using NSAIDs, glucocorticoids (<10 mg daily) or topical medications for psoriasis, must be on a stable dose for 4 weeks prior to Screening/Baseline 1 and remain on a stable dose during the study;
- Age 18-80 (patients older than 80 may be more likely to have concomitant osteoarthritis which may make it difficult to assess whether symptoms are related to PsA vs OA).
Exclusion Criteria:
-
Prior exposure to golimumab or another non-TNFi biologic (IL12/23i, JAKi, an IL17i, or an IL23i); prior exposure to a TYK2i is acceptable, but cannot be used during course of the study;
-
An adverse event that precludes use of another TNFi (development of drug-induced SLE, allergic reaction, serious infection, heart failure symptoms, demyelination at any point during use of therapy) or any other contraindication or substantial intolerance to a TNFi;
-
Use of moderate to high dose glucocorticoids (>10 mg);
-
Already meets the primary endpoint at Baseline; [cDAPSA low disease activity ≤ 14; IGA of psoriasis 0/1] In patients with psoriasis, cDAPSA can be 10-14 IF the Investigator Global Assessment of Psoriasis ≥ 2.
In patients without psoriasis, cDAPSA must be > 14 to meet eligibility requirements.
-
Currently pregnant or actively trying to conceive.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Guselkumab 100mg q4w
Guselkumab (GUS) 100mg every 4 weeks |
Guselkumab (GUS) subcutaneous injection
다른 이름들:
|
|
실험적: Guselkumab 100mg q8w
Guselkumab (GUS) 100mg every 8 weeks |
Guselkumab (GUS) subcutaneous injection
다른 이름들:
|
|
활성 비교기: Golimumab 50mg q4w
Golimumab (GOL) 50mg every 4 weeks |
Golimumab (GOL) subcutaneous injection
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Achievement of cDAPSA low disease activity
기간: 12 Months
|
Clinical Disease Activity in Psoriatic Arthritis (cDAPSA): a combination score of tender joint count, swollen joint count, patient assessment of pain, and patient global assessment of disease activity. Scale from 0-154 where higher figures indicate worse status. Remission is considered ≤4 and low disease activity >4 to ≤13. |
12 Months
|
|
Investigator Global Assessment of Psoriasis of Clear or Almost Clear
기간: 12 Months
|
Investigator global assessment (IGA) of psoriasis. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
12 Months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Minimal Disease Activity (MDA) using PSAID-12
기간: 6 and 12 months
|
Minimal Disease Activity (MDA) defines a satisfactory state of disease activity that includes 5 domains of PsA. 5/7 of the following criteria must be satisfied for MDA: patient global ≤ 2 (0-10), patient pain ≤ 2 (0-10), PSAID-12 <4 (0-10), TJC (Tender Joint Count) ≤ 1, SJC (Swollen Joint Count) ≤ 1, BSA (Body Surface Area) ≤ 3, and Leeds Enthesitis Index ≤ 1. |
6 and 12 months
|
|
Minimal Disease Activity (MDA) using HAQ-DI
기간: 6 and 12 months
|
(MDA) Minimal Disease Activity defines a satisfactory state of disease activity that includes 5 domains of PsA. Participant would need to achieve 5/7 of the following criteria: patient global ≤ 2 (0-10), patient pain ≤ 2 (0-10), HAQ-DI (Health Assessment Questionnaire Disability Index) < 0.5 (0-3), TJC (Tender Joint Count) ≤ 1, SJC (Swollen Joint Count) ≤ 1, BSA (Body Surface Area) ≤ 3, and Leeds Enthesitis Index ≤ 1. |
6 and 12 months
|
|
Change in PSAID-12
기간: 6 and 12 months
|
Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status. Negative changes from baseline indicate improvement in disease activity. |
6 and 12 months
|
|
PSAID-12 < 4
기간: 6 and 12 months
|
Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status. |
6 and 12 months
|
|
Change in DLQI
기간: 6 and 12 months
|
Dermatology Life Quality Index (DLQI) is a measure of skin disease activity. Calculated score of 0-30 where higher figures indicate worse status.Negative changes from baseline indicate improvement in disease activity. |
6 and 12 months
|
|
IGA Among Patients with BSA > 3% at Baseline
기간: 6 and 12 months
|
Investigator global assessment (IGA) of psoriasis among patients with BSA (Body Surface Area) >3% at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
6 and 12 months
|
|
IGA Among Patients with IGA ≥ 2 at Baseline
기간: 6 and 12 months
|
Investigator global assessment (IGA) of psoriasis among patients with IGA of 2 or more (≥ 2) at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
6 and 12 months
|
|
Change in Promis Fatigue
기간: 6 and 12 Months
|
Promis Fatigue is a measure of fatigue with a score from 8-40 where higher figures indicate worse status. A negative change indicates less overall fatigue. |
6 and 12 Months
|
|
Resolution of Dactylitis
기간: 6 and 12 Months
|
Dactylitis is assessed using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. These results are summed to produce a final score ranging from 0 to 20. A higher score indicates more severe dactylitis. Resolution of dactylitis is defined as a dactylitis score of 0 with a baseline dactylitis score >0. |
6 and 12 Months
|
|
Resolution of Enthesitis
기간: 6 and 12 Months
|
Enthesitis is assessed using the Leeds Enthesitis Index (LEI). This measure includes the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The total LEI score of 0-6 is based on evaluating each of these six sites as 0 or 1 based on the absence or presence of pain/tenderness. Resolution of enthesitis is defined as a enthesitis score of 0 with a baseline enthesitis score >0. |
6 and 12 Months
|
|
Change in BASDAI
기간: 6 and 12 Months
|
Change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) among patients with axial disease. The BASDAI sum score ranges from 0 to 10 and higher values indicate more active disease. Negative changes from baseline indicate improvement in disease activity. |
6 and 12 Months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Alexis Ogdie-Beatty, MD, MSCE, University of Pennsylvania
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- CNTO1959PSA3006
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .